Duobrii (halobetasol propionate and tazarotene; Ortho Dermatologics) has been made available for the topical treatment of plaque psoriasis in adult patients.
Duobrii combines halobetasol propionate, a corticosteroid, with tazarotene, a retinoid prodrug, into a lotion formulation. Each gram of Duobrii Lotion contains 0.1mg (0.01%) halobetasol propionate and 0.45mg (0.045%) tazarotene. The product is supplied in 100g tubes.
Unlike other topical corticosteroid products, the labeling for Duobrii does not include a duration limitation. In a long term safety study, continuous treatment was allowed for 24 weeks and as needed for up to 52 weeks. The study found that adverse events were infrequent and were consistent with those seen with topical corticosteroids and retinoids. The most common treatment-related adverse reactions included itching, pain, and irritation at the application site, as well as folliculitis.
Treatment with Duobrii should be discontinued once control is achieved. The total dosage should not exceed approximately 50g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
“The Duobrii formulation brings together 2 well-known ingredients in a unique lotion vehicle with low concentrations of halobetasol propionate and tazarotene, into a single, first-of-its-kind topical treatment,” said Bill Humphries, president, Ortho Dermatologics. “We are proud to provide plaque psoriasis patients this important new option, which offers strong efficacy and an extended duration of use in an advanced once daily lotion that can be dosed to clearance.”
For more information visit duobrii.com.